Top News

Tata Consultancy Services (TCS) has launched a new agentic AI platform for the pharmaceutical sector. Named TCS ADD AgentHub, it is designed for use in tasks related to drug development, clinical trials, and drug safety. According to the company, while AI agents can handle various repetitive tasks, final decision-making and oversight will remain with humans. TCS claims that the platform can enhance efficiency in pharmaceutical workflows.

**How ​​AgentHub Will Assist in Pharma Operations**
TCS ADD AgentHub enables pharmaceutical companies to create AI agents tailored to their specific needs and assign them various responsibilities. These agents can be utilized for tasks such as clinical data review, study design, protocol digitization, analysis of research papers and other materials, medical monitoring, and drug safety case processing. The platform is designed to integrate AI into research workflows while ensuring that human teams retain control and oversight.

**Platform Operates on a 'Human + AI' Model**
AgentHub operates on TCS's 'Human + AI' operating model. This means that while AI agents can manage the repetitive aspects of a workflow, the responsibility for governance and final decisions rests with humans. Research and clinical trials in the pharmaceutical sector generate vast amounts of data that may be fragmented across various systems. TCS is leveraging AgentHub to integrate AI agents into these workflows without eliminating human accountability.

**Claimed Efficiency Gains of Up to 40 Percent**
TCS claims that solutions built on AgentHub have helped improve efficiency in clinical data management by up to 40 percent. According to the company, metadata-based automation can reduce the effort required to set up clinical studies by up to 30 percent. Additionally, cost savings of up to 30 percent are claimed for end-to-end safety case processing. TCS also states that AI-based safety agents can reduce the effort involved in quality control tasks by up to 50 percent. These figures represent the company's claims, and they remain to be evaluated based on actual usage across various pharmaceutical organizations.

Disclaimer: This content has been sourced and edited from TV9. While we have made modifications for clarity and presentation, the original content belongs to its respective authors and website. We do not claim ownership of the content.